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Abstract: Tamoxifen is a prodrug that is primarily metabolized into the pharmacologically active
metabolite endoxifen and eventually into inactive metabolites. The herb curcumin may increase
endoxifen exposure by affecting phase II metabolism. We compared endoxifen and tamoxifen
exposure in breast cancer patients with or without curcumin, and with addition of the bio-enhancer
piperine. Tamoxifen (20–30mg per day (q.d.)) was either given alone, or combined with curcumin
(1200 mg three times daily (t.i.d.)) +/− piperine (10 mg t.i.d.). The primary endpoint of this study was
the difference in geometric means for the area under the curve (AUC) of endoxifen. Genotyping was
performed to determine CYP2D6 and CYP3A4 phenotypes. The endoxifen AUC0–24h decreased with
7.7% (95%CI:−15.4 to 0.7%; p = 0.07) with curcumin and 12.4% (95%CI:−21.9 to−1.9%; p = 0.02) with
curcumin and piperine, compared to tamoxifen alone. Tamoxifen AUC0–24h showed similar results.
For patients with an extensive CYP2D6 metabolism phenotype (EM), effects were more pronounced
than for intermediate CYP2D6 metabolizers (IMs). In conclusion, the exposure to tamoxifen and
endoxifen was significantly decreased by concomitant use of curcumin (+/− piperine). Therefore,
co-treatment with curcumin could lower endoxifen concentrations below the threshold for efficacy
(potentially 20–40% of the patients), especially in EM patients.
Keywords: tamoxifen; curcumin; piperine; pharmacokinetics; drug interactions
1. Introduction
Breast cancer is one of the most commonly diagnosed malignancies worldwide and one of
the leading causes of cancer-related deaths in women [1]. For decades, patients with estrogen
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receptor-positive breast cancer have been extensively treated with endocrine therapy such as tamoxifen.
Tamoxifen acts as a selective estrogen receptor modulator in breast cancer tissue, thereby reducing the
risk of disease recurrence and breast cancer-specific mortality [2].
Currently, there is a trend towards the use of natural herbs and dietary products among cancer
patients. Nearly 20–30% of all cancer patients, especially breast cancer patients, use herbal medicine
besides their conventional therapy [3]. Curcumin, also called “turmeric”, a spice recovered from the
roots of the Curcuma longa plant, is becoming increasingly popular among cancer patients because
of its supposed anti-cancer effects [4]. Curcumin is characterized by a poor bioavailability because
of its poor absorption and rapid metabolism [5]. Therefore, curcumin is often used in combination
with piperine (a component of black pepper). Piperine increases curcumin bioavailability 20-fold by
increasing curcumin absorption and inhibition of curcumin glucuronidation [6].
Tamoxifen shows a complex and multi-pathway metabolism, which mainly occurs in the liver.
Tamoxifen is metabolized into several (active) metabolites, through several phase I and phase
II metabolizing enzymes, mainly by the cytochrome P450 (CYP) enzymes CYP2D6 and CYP3A4
(Figure 1) [7]. Based on its relatively high plasma concentrations and potency, endoxifen is believed to
be one of the most important metabolites in the efficacy of tamoxifen therapy [7,8]. Moreover, endoxifen
is excreted (mainly in the feces) after phase II metabolism through UDP-glucuronyltransferases (UGTs)
and sulfotransferase (SULT) [8].
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A study in rats demonstrated an increase in tamoxifen plasma concentration of 33–64%, 70 
suggesting an inhibitory effect of curcumin on tamoxifen metabolism [9]. Several studies (both in 71 
vitro and in vivo) demonstrated that curcumin has an inhibitory effect on several CYP enzymes, such 72 
as CYP3A4 and CYP2D6 [10]. Another important effect of curcumin is its inhibition of phase II drug 73 
metabolism by inhibition of UGT. Furthermore, curcumin could potentially inhibit or induce several 74 
drug-efflux transporters (e.g., P-glycoprotein (P-gp), which may be inhibited or induced) [10–12].  75 
In this study, it was hypothesized that endoxifen plasma concentrations may increase when 76 
tamoxifen is administered with curcumin, mainly through UGT enzyme inhibition. In addition, 77 
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Figure 1. The ajor pri ary metabolite N-desmethyl-tamoxifen and the minor primary metabolite
4-hydroxytamoxifen are formed by N-demethylation and 4-hydroxylation of tamoxifen, through
CYP3A4 and CYP2D6 metabolism, respectively. Further CYP-mediated metabolism of these
metabolites results in the formation of 4-hydroxy-N-desmetyltamoxifen (endoxifen). Endoxifen is
ultimately metabolized through phase II metabolism into among others endoxifen–glucoronide through
UDP-glucuronyltransferases (UGTs) and also through sulfotransferase (SULT) enzymes.
A study in rats demonstrated an increase in tamoxifen plasma concentration of 33–64%, suggesting
an inhibitory effect of curcumin on tamoxifen metabolism [9]. Several studies (both in vitro and in vivo)
demonstrated that curcumin has an inhibitory effect on several CYP enzymes, such as CYP3A4 and
CYP2D6 [10]. Another important effect of curcumin is its inhibition of phase II drug metabolism
by inhibition of UGT. Furthermore, curcumin could potentially inhibit or induce several drug-efflux
transporters (e.g., P-glycoprotein (P-gp), which may be inhibited or induced) [10–12].
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In this study, it was hypothesized that endoxifen plasma concentrations may increase when
tamoxifen is administered with curcumin, mainly through UGT enzyme inhibition. In addition,
concomitant administration with the bio-enhancer piperine may potentiate effects on tamoxifen and
endoxifen plasma pharmacokinetics. In a pharmacokinetic cross-over study we therefore explored the
impact of curcumin—with and without piperine—on tamoxifen and endoxifen pharmacokinetics.
2. Results
2.1. Patient Characteristics
Seventeen patients were included in the study. One patient was excluded because of voluntary
withdrawal, resulting in 16 evaluable patients. Patient characteristics can be found in Table 1. DNA
analysis showed no variants for CYP3A4*22. As this polymorphism is considered most relevant
for CYP3A4, a predicted normal CYP3A4 phenotype for all study patients based on genotype was
assumed [13,14]. Based on CYP2D6 genotyping, seven patients (44%) showed an extensive CYP2D6
metabolism phenotype (EM), while seven other patients (44%) exhibited intermediate CYP2D6
metabolism (IM). The other two patients (12%) demonstrated ultra-rapid metabolism (UM) and
poor CYP2D6 metabolism (PM), respectively.
Table 1. Patient characteristics.
Characteristic N (%)
Patients 16 (100)
Randomization sequence
- ABC 9 (56)
- CBA 7 (44)
Adjuvant tamoxifen treatment 16 (100)
Age (Median, IQR) 45 (42–58)
Sex
- Female 15 (94)
- Male 1 (6)
Race
- Caucasian 15 (94)
- Arabic 1 (6)
Height (Median, IQR) 171 (167–176)
Weight (Median, IQR) 73 (65–91)
BMI (Median, IQR) 25 (23–29)
WHO Performance Status
- 0 13 (81)
- 1 3 (19)
Previous chemotherapy
- Yes 12 (75)# TAC 2 (13)# AC - paclitaxel 4 (25)# FEC - docetaxel 6 (37)
- No 4 (25)
Previous RTx
- Yes 10 (63)
- No 6 (37)
Tamoxifen dose
- 20 mg 15 (94)
- 30 mg 1 (6)
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Table 1. Cont.
Characteristic N (%)
Genotype
- CYP3A4*22# EM 16 (100)
- CYP2D6# EM 7 (44)# IM 7 (44)# PM 1 (6)# UM 1 (6)
Abbreviations: IQR = interquartile range; TAC = Docetaxel, doxorubicin, and cyclofosfamide; AC = doxorubicin
and cyclofosfamide; FEC = 5FU, epirubicine, and cyclofosfamide; RTx = radiotherapy; EM = extensive metabolism
phenotype; IM = intermediate metabolism phenotype; PM = poor metabolism phenotype; UM = ultra-rapid
metabolism phenotype.
2.2. Pharmacokinetics
In patients treated with tamoxifen and curcumin, the geometric mean AUC0–24h and Ctrough of
tamoxifen decreased 8.0% (95%CI: −14.1% to −1.4%, p = 0.02) and 7.1% (95%CI: −17.1% to 4.0%,
p = 0.25), respectively, compared to tamoxifen monotherapy (Table 2). Furthermore, AUC0–24h and
Ctrough of endoxifen decreased 7.7% (95%CI: −15.4% to 0.7%, p = 0.07), and 5.6% (95%CI: −15.6% to
5.5%, p =0.43), respectively, with concomitant curcumin treatment.
Table 2. Tamoxifen pharmacokinetics.
PK
Parameters
Tamoxifen
Monotherapy
(A)
Tamoxifen +
Curcumin (B)
Tamoxifen +
Curcumin +
Piperine (C)
Relative
Difference A vs
B (95%CI)
p-Value
Relative
Difference (A
vs C) (95%CI)
p-Value
Tamoxifen
AUC0–24h 5951 (20) 5460 (24) 5171 (23)
−8.0%
(−14.1 to −1.4) 0.02
−12.8%
(−19.2 to −5.9) <0.01
Ctrough 213 (27) 198 (28) 187 (24)
−7.1%
(−17.1 to +4.0) 0.25
−12.2%
(−21.5 to −1.8) 0.02
Cmax 356 (16) 324 (21) 313 (22)
−8.4%
(−16.4 to +0.5) 0.07
−11.1%
(−18.1 to −3.6) <0.01
Tmax
2.4
(1.9 to 3.1)
2.4
(1.9 to 3.0)
2.7
(1.9 to 3.8) 0.74 0.34
Endoxifen
AUC0–24h 597 (59) 556 (52) 518 (54)
−7.7 %
(−15.4 to +0.7) 0.07
−12.4%
(−21.9 to −1.9) 0.02
Ctrough 25 (60) 23 (53) 21 (55)
−5.6 %
(−15.6 to +5.5) 0.43
−12.4%
(−20.9 to −3.0) 0.01
Cmax 31 (56) 28 (50) 27 (51)
−7.1%
(−16.3 to +3.2) 0.20
−9.8%
(−20.1 to +1.8) 0.10
Tmax
2.0
(1.3 to 3.0)
1.7
(1.2 to 2.6)
1.8
(1.1 to 3.1) 0.88 0.62
4-hydroxy-tamoxifen
AUC0–24h 113 (31) 106 (24) 103 (28)
−6.3 %
(−11.6 to −0.73) 0.03
−8.2%
(−17.0 to +1.6) 0.11
Ctrough 4.4 (34) 4.2 (26) 4.1 (28)
−4.3 %
(−12.3 to +4.4) 0.45
−7.3
(−17.6 to +4.3) 0.26
Cmax 6.0 (32) 5.4 (26) 5.4 (31)
−10.0%
(−16.8 to −2.6) <0.01
−8.8%
(−20.0 to +4.0) 0.20
Tmax
2.7
(1.9 to 3.9)
2.4
(1.8 to 3.3)
2.8
(2.0 to 3.8) 0.42 0.37
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Table 2. Cont.
PK
Parameters
Tamoxifen
Monotherapy
(A)
Tamoxifen +
Curcumin (B)
Tamoxifen +
Curcumin +
Piperine (C)
Relative
Difference A vs
B (95%CI)
p-Value
Relative
Difference (A
vs C) (95%CI)
p-Value
N-desmethyl-tamoxifen
AUC0–24h 11596 (21) 10766 (24) 10084 (31)
−7.0%
(−13.1 to −0.6) 0.03
−12.4%
(−22.3 to −1.3) 0.03
Ctrough 463 (28) 430 (29) 411 (32)
−7.2%
(−15.0 to +1.2) 0.10
−10.9%
(−21.6 to +1.3) 0.08
Cmax 602 (21) 556 (24) 540 (32)
−7.2%
(−14.9 to +1.1) 0.09
−9.7%
(−20.2 to +2.3) 0.12
Tmax
2.6
(1.8 to 3.7)
1.7
(1.2 to 2.4)
2.1
(1.4 to 3.2) 0.24 0.88
Abbreviations: PK = pharmacokinetics; CI = Confidence Interval; AUC0–24h= area under the curve, timepoint 0 h to
24 h (expressed as geomean nM·h/mL (CV%)); Ctrough= minimum concentration (expressed as geomean nM/mL
(CV%)); Cmax= maximum concentration (expressed as geomean nM/mL (CV%)); Tmax= time until maximum
concentration (expressed as median h (IQR)); CV% = coefficient of variation; IQR = interquartile range.
When tamoxifen was administered with curcumin and piperine, the effects were more pronounced;
tamoxifen AUC0–24h and Ctrough decreased 12.8% (95%CI: −19.2% to −5.9%, p < 0.01) and 12.2%
(95%CI: −21.5% to −1.8%, p = 0.02), respectively, compared to tamoxifen monotherapy. The
endoxifen AUC0–24h decreased 12.4% (95%CI: −21.9% to −1.9%, p = 0.02), while the Ctrough
decreased 12.4% (95%CI: −20.9% to −3.0%, p =0.01). Further pharmacokinetic results are shown
in Table 2. Pharmacokinetic parameters for 4-hydroxy-tamoxifen and N-desmethyl tamoxifen showed
a decrease in almost every pharmacokinetic parameter when administered with curcumin—with
and without piperine—although only AUC0–24h of N-desmethyl tamoxifen and 4-hydroxytamoxifen
with curcumin and AUC0–24h of N-desmethyl tamoxifen with curcumin and piperine demonstrated a
significant difference.
When analyzing the CYP2D6-predicted phenotypes separately, both endoxifen and tamoxifen
showed a more pronounced decrease for both AUC0–24h and Ctrough (especially during treatment
with curcumin and piperine) in patients with an extensive metabolism, compared to those with an
intermediate metabolism (Table 3). In patients with an IM treated with curcumin and piperine, the
AUC0–24h decreased 5.3% (95%CI: −13.1% to +3.1%, p = 0.16) and 10.3% (95%CI: −23.5% to 5.3%, p =
0.14) for tamoxifen and endoxifen, respectively. In patients with an EM treated with curcumin and
piperine, the tamoxifen and endoxifen AUC0–24h decreased 22.0% (95%CI: −29.0% to −14.2%, p < 0.01)
and 18.4% (95%CI: −36.1% to 4.3%, p = 0.09), respectively. Ctrough showed similar results (Table 3).
Although, the interaction term was only significant for tamoxifen AUC0–24h and Ctrough with curcumin
and piperine. There was no period effect, which implicated no decline in tamoxifen nor endoxifen
plasma concentrations based on altered tamoxifen metabolism over time. Individual tamoxifen and
endoxifen AUC0–24h can be found in Figure 2 and in Supplementary Figure S1.
Table 3. Tamoxifen pharmacokinetics, based on CYP2D6 phenotype.
PK
Parameters
Tamoxifen
Monotherapy
(A)
Tamoxifen +
Curcumin (B)
Tamoxifen +
Curcumin +
Piperine (C)
Relative
Difference A vs
B (95%CI)
p-Value
Relative
Difference A vs
C (95%CI)
p-Value
Intermediate Metabolizers (IM)
Tamoxifen
AUC0–24h
5795
(4895–6859)
5427
(4313–6830)
5518
(4679–6508)
−7.2%
(−18.2 to +5.4) 0.19
−5.3%
(−13.1 to +3.1) 0.16 *
Tamoxifen
Ctrough
200
(160–251)
191
(146–249)
199
(167–237)
−5.9%
(−20.9to +11.9) 0.41
−1.3%
(−15.3 to 15.1) 0.84 *
Endoxifen
AUC0–24h
523
(362–755)
472
(339–656)
477
(340–669)
−9.4%
(−21.7 to +4.8) 0.14
−10.3%
(−23.5 to 5.3) 0.14
Endoxifen
Ctrough
21
(14–32)
19
(13–27)
19
(14–27)
−10.7%
(−28.2 to 11.2) 0.24
−8.3%
(−27.2 to 15.4) 0.38
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Table 3. Cont.
PK
Parameters
Tamoxifen
Monotherapy
(A)
Tamoxifen +
Curcumin (B)
Tamoxifen +
Curcumin +
Piperine (C)
Relative
Difference A vs
B (95%CI)
p-Value
Relative
Difference A vs
C (95%CI)
p-Value
Extensive Metabolizers (EM)
Tamoxifen
AUC0–24h
6077
(4882–7565)
5471
(4247–7047)
4836
(3720–6288)
−10.3%
(−19.7 to +0.3) 0.06
−22.0%
(−29.0 to −4.2) <0.01 *
Tamoxifen
Ctrough
218
(163–291)
199
(148–268)
170
(132–218)
−9.6%
(−26.4 to +11.2) 0.27
−24.6%
(−33.9 to −14.1) <0.01 *
Endoxifen
AUC0–24h
745
(576–963)
716
(574–893)
596
(495–717)
−5.7%
(−19.6 to +10.7) 0.39
−18.4%
(−36.1 to +4.3) 0.09
Endoxifen
Ctrough
30
(23–39)
31
(25–38)
25
(20–30)
−0.3%
(−12.8 to +13.9) 0.96
−17.2%
(−26.1 to −7.3) <0.01 *
Abbreviations: PK = pharmacokinetics; CI = Confidence Interval; AUC0–24h= Area under the curve, timepoint 0 h to
24 h (expressed as geomean nM·h/mL (95%CI)); Ctrough= minimum concentration (expressed as geomean nM/mL
(95%CI)); * Interaction term reached statistical significance (p < 0.05).Cancers 2019, 11, x 6 of 11 
 
 134 
Figure 2. Endoxifen and tamoxifen AUC0–24h per individual patient per treatment phase: (a) Tamoxifen 135 
AUC0–24h per individual patients per treatment phase. (b) endoxifen AUC0–24h per individual patients 136 
per treatment phase. Patients with an intermediate CYP2D6 metabolism (IM) were colored blue. 137 
Patients with an extensive CYP2D6 metabolism (EM) were colored black. Poor CYP2D6 metabolizers 138 
(PM) and ultra-rapid CYP2D6 metabolizers (UR) were colored green and red, respectively; *: decrease 139 
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Anorexia 1(6) 0 1(6) 
Pain 4(25) 0 2(13) 
Rash 1(6) 0 1(6) 
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three patients in tamoxifen AUC0–24h when tamoxifen was administered with curcumin and piperine,
compared to tamoxifen monotherapy.
2.3. Toxicities
There were no unexpected serious adverse events (SAE) during combined treatment with
curcumin or curcumin plus piperine related to the study procedures. There was one serious adverse
event, which was assumed to be not related to any of the study drugs (collapse with unknown origin).
Toxicity profiles were similar between the different treatment phases, although more hot flashes
and fatigue were observed in patients treated with curcumin +/− piperine compared to tamoxifen
monotherapy (Table 4). Interestingly, three patients suffered from grade 2–3 diarrhea during treatment
with curcumin and piperine, whereas none of the patients experienced diarrhea when treated with
tamoxifen monotherapy.
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Table 4. Adverse Events.
Adverse Event TamoxifenMonotherapy N (%) (A)
Tamoxifen with
Curcumin N (%) (B)
Tamoxifen with Curcumin
and Piperine N (%) (C)
Nausea 2(13) 1(6) 1(6)
Diarrhea 0 1(6) 3(19)
Constipation 2(13) 4(25) 1(6)
Fatigue 2(13) 3(19) 3(19)
Hot flashes 3(19) 5(31) 4(25)
Reflux 1(6) 1(6) 0
Dyspnea 0 1(6) 0
Anorexia 1(6) 0 1(6)
Pain 4(25) 0 2(13)
Rash 1(6) 0 1(6)
Hypophosphatemia 0 0 1(6)
Hyperlipidemia 1(6) 1(6) 1(6)
Legend: Number of patients with all Common Terminology Criteria for Adverse Events (CTCAE)-grade adverse
events when treated with tamoxifen with or without curcumin and piperine expressed as number of patients (% of
total number of patients).
3. Discussion
In this study, a modest but significant decrease was found in both tamoxifen and endoxifen plasma
concentrations during concomitant administration of tamoxifen and curcumin, compared to tamoxifen
monotherapy. This effect was even more pronounced when tamoxifen was administered with curcumin
and piperine. Furthermore, patients with an extensive CYP2D6 phenotype seem to be at greater risk of
experiencing this herb–drug interaction, compared to CYP2D6 intermediate metabolizers.
Since tamoxifen metabolism and excretion is complex and involves multiple enzymes and
transporter proteins, the likelihood of a drug–drug interaction (DDI) with modulators and inhibitors of
enzymes and drug-transporters (e.g., CYP3A4 and P-glycoprotein) involved in tamoxifen metabolism
is high [7,8]. Based on preclinical data, curcumin is a compound that could potentially lead to such
a DDI [10]. When designing our study, we based our hypothesis on preclinical data, as no studies
in cancer patients studying the effects of curcumin on the pharmacokinetics of anti-cancer drugs
were available in the literature. Cho et al. demonstrated an increase in tamoxifen exposure and
a decrease in 4-hydroxy-tamoxifen/tamoxifen AUC ratio, suggesting a decrease in CYP-mediated
metabolism or P-glycoprotein-mediated efflux of tamoxifen [9]. On the other hand, in vitro results
indicate an inhibitory effect of curcumin on phase II metabolism, in which enzymes such as UGT are
involved [10,15]. UGTs are also involved in the metabolism of tamoxifen (Figure 1), in theory resulting
in increased endoxifen plasma concentrations [15]. In contrast to the study in rats by Cho et al., we
found both a decrease in tamoxifen and endoxifen plasma concentrations. We do not have a conclusive
explanation for this observation, as several mechanisms might be involved. One of the limitations
of this study is that we could not further explore the mechanisms of this interaction. However, as
endoxifen plasma concentrations did not increase during concomitant treatment with curcumin and
piperine, an inhibitory effect on phase II metabolism is unlikely, as these results rather indicate phase
II induction. A more likely explanation is inhibition of CYP2D6, which is underlined by the larger
effect in EM patients. Although, this cannot be the only explanation, as tamoxifen concentrations
also decreased due to curcumin co-treatment, where an increase was expected if there was solely
an inhibitory effect on CYP2D6. Another explanation may be found in a potential interaction with
P-glycoprotein. This transporter, which is responsible for the efflux of tamoxifen out of the epithelial
cells into the gut and bile, was studied before in vitro and led to contrasting results (but especially
inhibition) [10,12,16]. However, in case curcumin acts as a P-glycoprotein inducer, tamoxifen and
metabolite plasma concentrations would all decrease, which is in line with our findings, resulting from
a diminished absorption of tamoxifen into the blood stream. Yet, the evidence supporting curcumin as
a P-glycoprotein inducer is limited.
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One of the main problems of clinical research with curcumin is to standardize the formulation
of curcumin. There are many curcumin formulations available. Potentially these formulations
may differ in bio-availability, which makes it difficult to determine the individual impact of these
formulations and to give general advisories [17]. Moreover, many of these formulations exist of
multiple non-standardized ingredients. In this study, standardized formulations of both curcumin and
piperine, of 1200 mg and 10 mg capsules, respectively, were used from a single production batch.
Moreover, curcumin has low bio-availability, and the suggested inter-patient variability is
high [4,18]. We only measured tamoxifen pharmacokinetics and did not determine plasma levels of
curcumin, which gives a possible limitation of this study since the magnitude of a possible interaction
may differ between patients depending on curcumin plasma levels [18]. However, a curcumin dose of
3.6 g q.d. is considered a significant plasma concentration and is therefore most likely to achieve a
significant drug interaction [18].
Furthermore, the interaction term for CYP2D6 metabolism only reached significance for tamoxifen
AUC0–24h and Ctrough when co-administered with curcumin and piperine. Since the design of this
study was not sufficient to detect a significant difference in other pharmacokinetic endoxifen and
tamoxifen comparisons, this result must be confirmed in future clinical trials.
Besides curcumin, piperine might also influence pharmacokinetics of tamoxifen and endoxifen
by itself [19]. Piperine affects the structure of the intestinal lumen and wall, resulting in a higher
passive drug influx. Concomitant piperine use might alter gastric emptying time in a dose- and time
dependent manner, and in addition, piperine is known to be a P-glycoprotein inhibitor in vivo [19,20].
Moreover, piperine might enhance plasma concentrations of several drugs because of the inhibition
of CYP enzymes (e.g., CYP3A4, CYP2D6) [19]. Therefore, the effect of piperine on tamoxifen and
endoxifen pharmacokinetics may not be underestimated, and the results in this study could not be
solely attributed to curcumin.
The relatively small effects on tamoxifen and endoxifen pharmacokinetics and the high
inter-patient variability of endoxifen (CV = 50–60%) in this study may seem of limited clinical relevance.
However, individual patients may be deprived from an optimal therapy, since tamoxifen and endoxifen
concentrations may drop below the threshold for efficacy (~16 nM for endoxifen) resulting from
co-treatment with curcumin [7,21]. This threshold is associated with a survival benefit, and 20–30% of
all treated patients had an endoxifen plasma concentration below this threshold, and an additional 20%
had endoxifen plasma concentrations just above this threshold [21–23]. This scenario is particularly
the case in patients with an extensive metabolism CYP2D6 phenotype, as effects of curcumin with and
without piperine were most pronounced in this group of patients.
4. Materials and Methods
This two-arm, three-period, randomized, cross-over study was performed between January 2017
and May 2018 at the Erasmus University Medical Center. The study was approved (approval date:
19 January 2017, ethics committee code: METC-16-679) by the local ethics committee of the Erasmus
University Medical Center and competent authority in accordance to the declaration of Helsinki, and
it was registered at the European Clinical Trials Database (EudraCT 2016-004008-71) and the Dutch
trial registry (www.trialregister.nl; number NTR6149).
4.1. Patients
We included patients who had a histological or cytological confirmed diagnosis of breast cancer
with an indication for tamoxifen treatment who were at least 18 years of age. In addition, an Eastern
Cooperative Oncology Group (ECOG) performance status of 0 or 1, and adequate hematological, renal,
and liver function (defined as a CTCAE grade of ≤1) were required. Patients were able and willing to
abstain from curry, grapefruit (juice), (herbal) dietary supplements, and herbals or over-the-counter
medication (except for paracetamol and ibuprofen) for the duration of the study. Patients were excluded
if they had known impaired drug absorption (e.g., gastrectomy), serious illness, or medically unstable
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conditions requiring treatment (e.g., infection, heart failure) or if they used strong CYP3A4, CYP2D6,
UGT, or P-glycoprotein inhibitors or inducers. All included patients gave written informed consent.
4.2. Study Procedures
Patients received tamoxifen at the same dose for at least 28 days before entering the study to
ensure steady-state pharmacokinetics. No dose alterations were allowed after inclusion in the study.
Patients were digitally randomly assigned into two sequence groups, using block randomization, to
rule out sequence effects. Tamoxifen was administered at a constant dose (20–30 mg q.d.) during three
consecutive cycles. During cycle one, patients received tamoxifen monotherapy; in cycle two, patients
swallowed tamoxifen concomitant with curcumin (three times daily 1,200 mg), and in cycle three,
tamoxifen was taken concomitantly with curcumin and piperine (three times daily 1,200 mg and three
times daily 10 mg, respectively) in the first sequence group or vice versa in the other group. Curcumin
and piperine were taken at predefined time points (10 AM, 4 PM, and 10 PM). Patient compliance was
assessed through a patient diary until the end of study after three consecutive cycles. Furthermore,
CYP2D6 and CYP3A4*22 mutational analyses were performed.
4.3. Pharmacokinetic Sampling
Patients were admitted to the hospital on days 28, 56, and 84 of the study for
pharmacokinetic blood sampling. Blood samples for determination of tamoxifen, 4-hydroxytamoxifen,
n-desmethyl-tamoxifen, and endoxifen pharmacokinetics were obtained at predefined time points
(t = 0 (before tamoxifen intake); and 0.5 h; 1 h; 1.5 h; 2 h, 2.5 h; 3 h; 3.5 h; 4 h; 6 h; 8 h; 12 h; and 24 h after
tamoxifen intake). Blood samples were processed into plasma within 30 minutes by vortex mixing
and centrifugation for 10 min at 2500–3000× g at 4 ◦C. Plasma concentrations were measured using
a validated liquid chromatography with a tandem mass spectrometry method (UP-LCMS/MS) [24].
Predefined pharmacokinetic parameters were tamoxifen and endoxifen exposure (expressed as
dose-corrected area under the curve from the pre-infusion time point until 24h (AUC0–24h)), maximum
concentration (Cmax), time until maximum concentration (Tmax), and lowest plasma concentration
(Ctrough). Pharmacokinetic outcomes were calculated using Phoenix WinNonlin version 8.1 (Pharsight,
a Certara Company, Princeton, NJ, USA).
4.4. Toxicity
Toxicity rates during tamoxifen monotherapy and tamoxifen concomitantly with curcumin
+/− piperine were determined during patient follow-up until the end of the study using Common
Terminology Criteria for Adverse Events (CTCAE version 4.0, National Cancer Institute, Bethesda,
MD, USA) and by evaluating the patient diaries.
4.5. Statistical Analysis
A difference in systemic exposure (AUC0–24h) to endoxifen of 25% between treatment cycles was
considered to be clinically relevant. It was assumed that the within patient standard deviation in
endoxifen pharmacokinetics was 20% [25]. Given a power of 80%, this resulted in a sample size of 16
evaluable patients [26].
Analyses of AUC0–24h , Ctrough, and Cmax were performed on log-transformed observations since
these were assumed to follow a log-normal distribution [27]. Estimates for the mean differences in (log)
AUC0–24h, Ctrough, and Cmax were obtained for the two comparisons (i.e., curcumin versus tamoxifen
monotherapy, and curcumin plus piperine versus tamoxifen monotherapy) separately using a linear
mixed effect model with treatment, sequence, and period as fixed effects and subject within sequence
as a random effect [28]. Variance components were estimated based on restricted maximum likelihood
(REML) methods, and the Kenward–Roger method of computing the denominator degrees of freedom
was used [28]. Since two primary comparisons were made, a Bonferroni correction was applied to
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correct for multiple testing (two-sided alpha of 5%/2 = 2.5%). Tmax was analyzed by means of the
Wilcoxon signed-rank test and described with medians and interquartile ranges.
For a comparison between extensive and intermediate CYP2D6 phenotypes, an interaction
term between metabolism and treatment was added to the linear mixed effects models. Only if
the interaction term turned out to be significant, subsequent subgroup analyses were performed.
Toxicity was described as the incidence of toxicity per phase. This was corrected for baseline
toxicity and was only taken into account in case of an increase in CTCAE grade per cycle. Since the
design of this study was not appropriate to detect a significant difference in toxicity, these results had
a descriptive character.
5. Conclusions
This was the first study that investigated the influence of curcumin (with and without piperine) on
tamoxifen pharmacokinetics. The use of curcumin (with and without piperine) significantly decreased
tamoxifen and endoxifen pharmacokinetics, especially in EM patients. Patients may be deprived
from optimal tamoxifen treatment, and endoxifen plasma levels may even drop below the threshold
for treatment efficacy. Therefore, patients should be advised to stop curcumin use during tamoxifen
treatment, or treatment efficacy of tamoxifen should be adequately monitored.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/3/403/s1,
Figure S1: Time-concentration (AUC) curves for both tamoxifen (A) and endoxifen (B) for every individual patient
(coded as patient 001–016).
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